|
Synonyms: ATN161 | N-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-asparaginamide
Compound class:
Peptide
Comment: ATN-161 is a penta-peptide integrin α5β1 antagonist [5]. It interferes with the interaction between the integrin on endothelial cells and fibronection in the extracellular matrix (ECM) [3]. ATN-161 was primarily proposed as an anti-tumour agent with potential to disrupt neoangiogenesis [1,5,7]. It has subsequently been explored for antimicrobial/anti-infection potential [2,4,6,9].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| ATN-161 was progressed as a clinical anti-tumour agent. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | Phase 2 Interventional | Attenuon | ||
| NCT00352313 | ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma | Phase 1/Phase 2 Interventional | National Institutes of Health Clinical Center (CC) | ||